

References

I-236

1. Kuntz N, Wagner K, East L, etc. Casimersen treatment in eligible patients with Duchenne muscular dystrophy: Safety, tolerability, and pharmacokinetics over 144 weeks of treatment. *Neuro Disorders*. 2020;30(S1):S130-S131.
2. Amondys 45 (Casimersen), injections [package insert]. Sarepta Therapeutics, Inc. Cambridge, MA. Revised 02/2021.
3. Clinical Pharmacology™ Compendium. 2022. Tampa FL: Gold Standard, Inc. Casimersen.
4. Micromedex DrugDex Compendium®. 2022. Casimersen.
5. Casimersen In: AHFS Drug Information Online Electronic Medical Library. Bethesda, MD: American Society of Health-System Pharmacists. Updated March 15, 2021.
6. Wagner KR, Kuntz NL, Koenig E, et al. Safety, tolerability, and pharmacokinetics of casimersen in patients with Duchene muscular dystrophy amenable to exon 45 skipping: A randomized, double blind, placebo-controlled, dose-titration trial. *Muscle and Nerve*. 2021;64:285-292.